Ask about this productRelated genes to: PBX1 antibody
- Gene:
- PBX1 NIH gene
- Name:
- PBX homeobox 1
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 1q23.3
- Locus Type:
- gene with protein product
- Date approved:
- 1990-09-10
- Date modifiied:
- 2016-05-17
Related products to: PBX1 antibody
Related articles to: PBX1 antibody
- Myoepithelial tumors (MET) of soft tissue and bone comprise a rare group of neoplasms unified by partially overlapping morphology and so called myoepithelial immunophenotype. Historically, MET have long posed diagnostic and prognostic challenges. Grading and risk stratification have relied largely on the presence of cytologic atypia. Recent molecular and epigenetic studies have fundamentally revised this concept, demonstrating that MET represent a biologically heterogeneous family rather than a single disease entity. Soft tissue (mostly deep-seated) and osseous MET frequently harbor recurrent gene fusions, most commonly involving FET family genes (EWSR1 or less often FUS) with partners such as POU5F1, PBX1, PBX3, KLF15, KLF17, and ZNF444, and more rarely non-FET fusions including SS18::POU5F1. These fusion types correlate with reproducible clinicopathologic patterns and, in emerging outcome datasets, with subtype-specific differences in behavior. In contrast, superficially located adnexal tumors with ductal differentiation - representing true cutaneous mixed tumors/myoepitheliomas - typically lack EWSR1/FUS rearrangements and instead show PLAG1 rearrangements, supporting a bona fide myoepithelial origin and close relationship to PLAG1-driven salivary gland counterparts. Additional complexity arises from SMARCB1-deficient, fusion-negative tumors and a small subset lacking identifiable recurrent drivers, as well as substantial overlap in morphology and immunophenotype with multiple MET mimics, contributing to diagnostic misclassification when using morphology and immunohistochemistry alone. To address these issues, we synthesize clinicopathologic, molecular, methylomic and pooled outcome data across major MET subgroups from recent multi-institutional cohorts, highlighting pronounced epigenetic and clinical heterogeneity and providing practical diagnostic guidance for surgical pathologists. We propose a molecularly informed classification framework that improves diagnostic precision, clarifies terminology - particularly distinguishing PLAG1-rearranged cutaneous salivary-gland analogs from fusion-associated soft tissue/bone sarcomas with myoepithelial-like phenotype - and lays a foundation for refined prognostic stratification and future therapeutic studies. - Source: PubMed
Publication date: 2026/05/06
Michal MichaelDermawan Josephine K - Pre-B-cell leukemia homeobox 1 (PBX1) is a transcription factor involved in diverse cellular processes, but its role in colorectal cancer (CRC) remains incompletely understood. In this study, we show that PBX1 is downregulated in CRC tissues and cell lines. Functional experiments revealed that PBX1 overexpression inhibits proliferation, migration, and invasion, but paradoxically suppresses apoptosis, suggesting a dual regulatory role. Transcriptome and CUT&Tag profiling identified BCL2L1 as a direct transcriptional target of PBX1. PBX1 binds the BCL2L1 promoter and enhances Bcl-xL expression, contributing to apoptotic resistance. BCL2L1 knockdown reversed the anti-apoptotic effects of PBX1 and restored apoptosis levels. Upon 5-fluorouracil (5-FU) treatment, PBX1 overexpression reduced cell viability, while concurrent BCL2L1 knockdown significantly enhanced drug sensitivity. In vivo, xenograft experiments demonstrated that PBX1 overexpression suppressed tumor growth, which was further augmented by BCL2L1 knockdown. These results support the dual role of PBX1 in simultaneously inhibiting tumor growth while promoting cell survival through the BCL2L1-Bcl-xL axis. This regulatory interaction may influence tumor persistence and therapeutic response in CRC. - Source: PubMed
Publication date: 2026/05/05
Lin HaoSu TingLiu YingDeng RuilanLi JieLin XuanhaoKe QiaolingLuo YijingMeng LeleLiang BinSong XuhongHuang DongyangXie Lingzhu - To determine whether circulating PBX1 is associated with AWGS2019-defined sarcopenia phenotypes in older adults, and whether alanine-related metabolites mediate the PBX1-ASMI association. - Source: PubMed
Publication date: 2026/05/04
Meng XiangyuanZhao ZhenhuMao ShuhuaYu JianingLiu YuqinYang XingxiangZhang XinGuo RuihanYang ShuranLiang ZhuoshuaiWang FengdanSun LanchaoZhao HuiLiu JinyuGao Tianlin - There are currently no clinically validated markers for taxane sensitivity in metastatic castration-resistant prostate cancer (mCRPC), so we aimed to predict docetaxel response from circulating cell-free DNA. We identified 180 patients with pre-treatment plasma specimens collected within 12 months of starting docetaxel for mCRPC at our institution. 138 underwent ultra-low pass whole genome sequencing (ULP-WGS), and tumor fractions (TFx) and copy number alterations (CNAs) were derived using ichorCNA. 79 samples with TFx > 0.04 underwent targeted panel sequencing (TPS). TP53 mutation was significantly associated with docetaxel non-response (p = 0.018); deletions involving bands located in arms 11p, 11q, 10q and 3p were enriched in responders, and amplifications in regions of 1p and 6q were enriched in non-responders. Transcription factor (TF) binding activity was inferred using Griffin, which identified TFs (ZSCAN4, CTCF, PHOX2B) with trends towards increased activity in non-responders (n = 22) and others (including PBX1, MYBL2, OSR2, PDX1 and ZIC2) in responders (n = 24). A combined ensemble binary classifier generated through XGBoost integrating these feature sets to predict docetaxel response outperformed models derived from any single feature set, achieving a training area-under-the-ROC curve of 0.87. Pre-cabazitaxel specimens, representing a docetaxel-resistant population, were used for external validation, with a concordance of 79.6% for predicting non-response. - Source: PubMed
Publication date: 2026/04/28
Chen David DZimmer AnatYang David DFrancini EdoardoPatton RobertCrowdis JettChandra PoojaBin Riaz IrbazHanratty BrianRickles-Young MicahTsuji JunkoCibulskis CarrieFleharty MarkWhelpley BridgetReardon BrendanPark JihyeNelson Peter SHuang Franklin WVan Allen Eliezer MHa GavinChoudhury Atish D - PLAG1 gene fusions have been identified in a subset of uterine sarcomas and were historically associated with myxoid morphology. However, recent evidence shows that not all cases demonstrate myxoid features or conventional smooth muscle immunophenotype. Herein, we present 11 cases of PLAG1-rearranged uterine mesenchymal tumours to further characterize their clinicopathologic, immunohistochemical and molecular profiles. - Source: PubMed
Publication date: 2026/04/22
Cai MengyuanZuo KeYu LinCheng YufanBi RuiGe HuijuanYang WentaoTu Xiaoyu